Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the best dose and side effects of venetoclax and how well it
works when given with combination chemotherapy in treating patients with newly diagnosed
acute myeloid leukemia or advanced myelodysplastic syndromes. Venetoclax may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as daunorubicin, cytarabine work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Giving venetoclax together with combination chemotherapy may work better in
treating patients with acute myeloid leukemia.